Ephylone
Viewing r1 — May 11, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Ephylone (N-ethylpentylone) is a synthetic stimulant of the substituted cathinone class. It is a structural analog of pentylone, shifted toward potent reuptake inhibitor by its N-ethyl group. It blocks the recycling of dopamine, norepinephrine, and serotonin, producing the stimulation and euphoria that define its effects.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
cocaine, amphetamine, MDPV +3 morecocaine, amphetamine, MDPV, methylone, mephedrone, eutylone show less
Synthesized in Germany in the 1960s as a potential antidepressant, it was never brought to market.[2] It appeared on illicit markets in 2014 and spread as counterfeit MDMA, becoming the most-seized synthetic cathinone in the United States by 2017.[3] It is now permanently Schedule I in the United States and Schedule II under the UN 1971 Convention.[4]
Subjective effects include euphoria, stimulation, wakefulness, mild empathogenic warmth, and increased energy. The experience is stimulant-dominant — a surge of drive and energy with a thin layer of warmth that falls well short of MDMA's emotional depth.[3] Compulsive redosing, anxious overstimulation, and a prolonged dysphoric comedown are characteristic unwanted effects.
Ephylone carries high dependence potential and significant toxicity, linked to 151 overdose deaths in the United States between 2015 and 2018.[5][6][7] The gap between an active and dangerous dose is narrow, and the pharmacological drive to redose pushes toward cardiovascular collapse and dangerous overheating.[8][9] No controlled human studies exist — evidence comes from animal pharmacology, forensic cases, and emergency department reports.
History[edit]
Discovery
Ephylone was first synthesized in Germany in the 1960s by researchers at Boehringer Ingelheim, exploring cathinone analogs as treatments for depression and fatigue.[2] It appeared in a 1969 US patent alongside related compounds including pentylone. Animal testing confirmed stimulant activity, but it was never advanced to clinical trials.[3]
Emergence on illicit markets
Ephylone appeared on US drug markets in 2014 and by 2017 was the single most commonly seized synthetic cathinone in the country.[3] It was routinely sold as counterfeit MDMA — users expecting MDMA doses unknowingly consumed ephylone at levels far above its active range.[10][2]
Regulatory response
The DEA temporarily placed ephylone in Schedule I in August 2018, citing 151 overdose deaths since 2015;[5] permanent scheduling followed in June 2021.[4] The WHO Expert Committee recommended Schedule II under the 1971 Convention in 2018.[11]
Ephylone's informal name follows cathinone naming convention: the "e" prefix marks the N-ethyl substitution that distinguishes it from pentylone. Alternative designations — bk-EBDP and N-ethylnorpentylone — appear in regulatory documents but never entered popular usage. Ephylone's notoriety comes almost entirely from its role as an undetected MDMA adulterant.
Chemistry[edit]
Structural class
Ephylone belongs to the substituted cathinone family — synthetic stimulants derived from cathinone, the active alkaloid of the khat plant. It also carries a 3,4-methylenedioxy ring, giving it partial structural resemblance to MDMA and methylone.[13] Its molecular formula is C₁₄H₁₉NO₃ (249.30 g/mol).
The critical difference from its close structural analog pentylone is a single substitution: an N-ethyl group instead of N-methyl on the amine nitrogen.[13] This change shifts the pharmacological profile away from the MDMA-like releaser category into the reuptake-inhibitor class — placing it pharmacologically closer to cocaine than to MDMA.
Pharmacology[edit]
Mechanism of action
Ephylone blocks the reuptake of dopamine, norepinephrine, and serotonin — preventing these neurotransmitters from being recycled, leaving them to accumulate and keep firing.[1] Unlike MDMA, it does not force the transporters to release stored neurotransmitter; it only blocks the return pathway.[14][15]
Ephylone binds most strongly to the DAT, with roughly ten times weaker affinity for serotonin.[1] This dopamine-dominant pattern predicts strong reinforcement and high compulsive use potential.[9] A residual serotonergic component from the methylenedioxy ring[13] likely explains the mild empathogenic warmth some users notice, though without serotonin release this falls far short of MDMA.[16]
Pharmacokinetics
No controlled human pharmacokinetic studies have been published. Oral onset is reported at 15–30 minutes, with total duration of 4–8 hours — figures from community consensus, not clinical data.safety citation needed The liver breaks it down through multiple pathways,[17] and active metabolites may extend effects.[18]
Neuroscience[edit]
Where it acts
Ephylone amplifies dopamine signaling in the mesolimbic mesolimbic pathway — the brain circuit underlying euphoria and the drive to repeat rewarding behaviors.[9] Chronic exposure builds up a protein called ΔFosB in the striatum, which reshapes gene expression in reward circuits and drives the transition from recreational use to compulsive seeking.[6]
Why it matters
Withdrawal depletes serotonin and norepinephrine, producing low mood, increased aggression, and elevated stress hormones.[6] Sex differences exist: females self-administer more at higher doses, while males are more vulnerable to dangerous overheating.[19]
Ephylone's dopamine-dominant profile means it drives the urge to obtain the drug more than the actual pleasure of taking it.[16] This explains why use escalates even as enjoyment fades — a hallmark of addiction.[7]
Whether ephylone causes lasting brain damage — as opposed to temporary adaptation — remains unknown. Serotonin depletion seen during withdrawal in mice[6] could represent a short-term adjustment or permanent damage to serotonergic nerve terminals. The broader cathinone class is linked to neurotoxic potential,[20] but ephylone-specific data are absent.
Subjective Effects[edit]
Ephylone's experience is defined by forceful stimulation — wakefulness, restless energy, and a social drive — underlaid by a thin layer of warmth that falls short of true emotional opening. The stimulant character dominates; at higher doses or with repeated dosing, warmth gives way to agitation.
Users familiar with MDMA should expect something quite different: less emotional depth, more raw stimulant energy, and substantially more pressure to redose.[3] Pharmacologically it sits between MDMA and MDPV — sharing the methylenedioxy ring of entactogens while operating through the reuptake-inhibiting mechanism of powerful stimulants.
Effect Grid
Clear stimulation with pronounced cognitive euphoria and sustained wakefulness. Focus enhancement and motivation enhancement are noticeable. Some users report empathogenic warmth and emotional enhancement, though the pharmacological profile (pure reuptake inhibition, no serotonin release) predicts a more stimulant-dominant experience than MDMA.
Bruxism and muscle tension become apparent. Heart rate and blood pressure are elevated. Appetite suppression is marked, and excessive sweating and temperature dysregulation may emerge. The compulsive redosing urge — a defining feature of ephylone's DAT-selective profile — becomes a significant factor at this tier.
Insomnia is likely for 6+ hours post-dose. Aftereffects include depressed mood, irritability, and fatigue lasting 6–24 hours.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Color enhancement
Physical fatigue · Wakefulness · Dry mouth · Heart rate perception changes · Pupil dilation · Restlessness · Tactile euphoria · Bruxism · Dehydration sensation · Excessive sweating · Muscle tension · Respiratory stimulation · Spontaneous body sensations · Tingling / electric sensations · Bodily lightness · Dizziness · Headache · Laughter fits · Nausea · Nystagmus (eye wobbles) · Sexual arousal enhancement · Vibrations / buzzing · Trembling · Vomiting
Pupil dilation · Restlessness · Tactile euphoria · Bruxism · Dehydration sensation · Excessive sweating · Muscle tension · Respiratory stimulation · Spontaneous body sensations · Tingling / electric sensations · Bodily lightness · Dizziness · Headache · Laughter fits · Nausea · Nystagmus (eye wobbles) · Sexual arousal enhancement · Vibrations / buzzing · Trembling · Vomiting
Aesthetic enhancement · Openness enhancement · Motivation enhancement · Cognitive dysphoria · Cognitive flexibility · Focus enhancement · Immersion enhancement · Information processing enhancement · Introspection enhancement · Novelty enhancement · Pattern recognition enhancement · Suggestibility enhancement · Thought connectivity · Analysis enhancement · Creativity enhancement · Humor enhancement · Language enhancement · Confusion · Memory fragmentation · Thought disorganization · Thought loops
Cognitive dysphoria · Cognitive flexibility · Focus enhancement · Immersion enhancement · Information processing enhancement · Introspection enhancement · Novelty enhancement · Pattern recognition enhancement · Thought connectivity · Analysis enhancement · Creativity enhancement · Humor enhancement · Language enhancement · Confusion · Memory fragmentation · Thought disorganization · Thought loops
Empathy enhancement · Anhedonia · Anxiety suppression · Emotional lability · Irritability · Catharsis · Dysphoria · Simultaneous emotions
Irritability · Catharsis · Dysphoria · Simultaneous emotions
Communication enhancement · Sociability enhancement · Emotional susceptibility · Trust enhancement · Flow state · Boundary dissolution
Flow state · Boundary dissolution
Timeline
Initial alertness and subtle mood shift emerge. Slight sympathomimetic activation — faint heart rate awareness — signals the compound's arrival.
Building stimulation and cognitive euphoria. Heart rate increases noticeably. Appetite suppression sets in and sociability begins to rise.
Maximum stimulation, euphoria, and wakefulness. Bruxism, sweating, and temperature dysregulation are most prominent. Compulsive redosing urge is strongest during this phase.
Stimulation persists but euphoria gradually fades. Irritability and dysphoria begin to emerge. Residual wakefulness continues despite declining subjective reward.
Stimulation recedes toward baseline. Fatigue, depressed mood, and irritability intensify. Physical discomfort — jaw soreness, muscle tension — becomes more noticeable as stimulation withdraws.
Residual insomnia, depressed mood, cognitive fatigue, appetite suppression, and irritability persist well beyond the subjective experience. This is not a positive afterglow but a stimulant aftermath.
⚠ Do not drive or operate heavy machinery for at least 12 hours after last dose — stimulant aftereffects impair reaction time and judgment even after subjective effects have diminished.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- —
- Physical
- Moderate
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- cocaine · amphetamine · MDPV
Toxicity
Acute toxicity
Ephylone is linked to 151 overdose deaths in the United States between 2015 and 2018.[5] No human lethal dose has been established, and no controlled dose-finding studies exist.
Blood concentrations in fatal cases range from 0.01 to 10.6 mg/L,[8][10] while clinical intoxication cases present at much lower levels (7–170 ng/mL).[1] This gap suggests a steep concentration-toxicity curve — small dose increases can shift from intoxication to life-threatening territory.
Adverse effects
Documented adverse effects include[21][1][10][20]:
- Heart and circulation: rapid heartbeat, high blood pressure, irregular heartbeat
- Brain and nervous system: hallucinations, agitation, confusion, excited delirium, seizures, coma
- Metabolic: dangerous overheating, muscle breakdown, metabolic acidosis
- Kidneys: acute kidney injury secondary to muscle breakdown
- Fatal: multi-organ failure
Excited delirium
Ephylone is disproportionately associated with excited delirium — extreme agitation, dangerous overheating, and cardiovascular collapse.[10][1] Both postmortem case series and clinical reports identify this as a characteristic toxicity pattern. Whether this reflects a unique pharmacological property or results from MDMA-dose substitution exposing users to far higher amounts is unresolved.
Overheating
Dangerous body temperature elevation is documented in both animal studies and human cases.[19] Male animals are more vulnerable to overheating than females.
Psychological risks
High doses can produce paranoia, hallucinations, and delusional thinking from excessive dopamine stimulation.[16] Post-use depression from monoamine depletion and increased aggression during withdrawal are also documented.[6] In UK emergency department presentations, hallucinations occurred in 44% of cases (4/9), with agitation and confusion each present in 67%.[21]
Tolerance and dependence
Animal models consistently indicate high dependence potential. Ephylone fully substitutes for methamphetamine and cocaine in drug discrimination tests — the strongest preclinical indicator of stimulant abuse potential.[2] In zebrafish models, it showed the highest abuse liability among methylenedioxy cathinones tested.[7]
Withdrawal in mice produces serotonin and norepinephrine depletion, depressive behavior, increased aggression, and elevated stress hormones.[6] Female mice self-administer more than males at higher doses.[19] No human withdrawal studies have been published.
Drug interactions
Serotonin toxicity. Combining ephylone with serotonergic drugs — SSRIs, SNRIs, monoamine oxidase inhibitors, triptans, tramadol, linezolid, or lithium — raises the risk of serotonin syndrome: a dangerous overheating and seizure response.[20] The combination with tramadol is classified as lethal, though not verified by a published case report.safety citation needed
Cardiovascular overload. Combining ephylone with other stimulants — MDMA, amphetamines, cocaine — or drugs that affect heart rhythm adds compounding cardiovascular risk: rapid heartbeat, high blood pressure, and dangerous overheating.[22][23] The combination with MDMA is classified as dangerous, though unverified by published case report.safety citation needed
The interaction with alcohol is unknown — no published data on the ephylone–alcohol combination exist.
Contraindications
The following are inferred from ephylone's pharmacology and the general cathinone class safety profileinferred:
- MAO inhibitors (absolute) — risk of dangerously high blood pressure and serotonin toxicity
- Pre-existing heart conditions (absolute) — stimulant activity produces rapid heartbeat, high blood pressure, and irregular heartbeat that may be fatal in people with structural heart disease
- Seizure disorders (relative) — stimulant cathinones lower seizure threshold[20]
- Liver impairment (relative) — impaired metabolism may increase exposure and toxicity risk[17]
- Concurrent serotonergic medication (relative) — SSRIs, SNRIs, and triptans increase serotonin syndrome risk
- Hot environments and physical exertion (relative) — heat and vigorous activity potentiate documented overheating[19]
- Pregnancy and breastfeeding (absolute) — no reproductive toxicity data exist; exposure cannot be considered safe
Harm Reduction[edit]
Forms & Identification
Ephylone is most dangerous when it arrives unannounced — sold as MDMA or another substance. The methylenedioxy ring means ephylone produces color reactions similar to MDMA with Marquis and Mecke reagents, making visual distinction difficult. Only laboratory-grade analysis (GC-MS, FTIR) or drug checking services can confirm identity with certainty.
The wide range of physical forms — powder, crystal, rock, capsule, and tablet — means no visual inspection rules ephylone out. If a substance sold as MDMA produces unexpectedly stimulating, restless, or prolonged effects, ephylone or a similar cathinone should be suspected.
Guidelines
- Test every substance before use — reagent kits as a minimum, drug checking services where available.
- Start with the lowest plausible dose and wait at least 90 minutes before considering redosing. Onset can be delayed and stacking doses is a primary risk factor for toxicity.
- Designate a sober sitter who knows what was taken and when.
- Stay cool and hydrated — avoid hot environments, vigorous dancing, and layered clothing. Sip water steadily but do not overhydrate.
- Do not redose in pursuit of fading effects. The dopamine-dominant profile makes the compulsive redosing urge strong, but each additional dose increases cardiovascular and overheating risk without proportionally increasing desired effects.
- Set a hard limit on total dose and number of redoses before the session begins, and give the remaining supply to the sitter.
Set & Setting
Ephylone's high dopamine activity makes it particularly sensitive to environment. Overstimulating settings — loud music, crowds, heat — can push the experience from energized to anxious or agitated. A cool, controlled environment reduces the risk of overheating and escalating agitation.
The compulsive redosing pattern is strongest in social settings where repeated dosing feels normalized. A sober companion who tracks time since the last dose is one of the most effective single interventions.
Aftercare & integration. The comedown from ephylone can be prolonged — monoamine depletion produces low mood, irritability, fatigue, and difficulty sleeping that may persist for days. Prioritize sleep and eat calorie-dense food even if appetite is absent.
Avoid using other stimulants, caffeine, or additional ephylone to manage the comedown — this extends the depletion cycle. Light physical activity can help restore mood baseline faster than bed rest. If low mood, aggression, or anxiety persists beyond a week, consult a medical professional.
Recovery & Support
Ephylone's pharmacological profile — strong dopamine reuptake inhibitor, robust ΔFosB accumulation, and persistent conditioned reward — places it among the synthetic cathinones with highest compulsive use potential. Recognizing a pattern of escalating use, inability to limit redosing, or continued use despite negative consequences is the first step.
Stimulant-specific support resources include SAMHSA's National Helpline (1-800-662-4357, US), SMART Recovery, and local addiction services. No ephylone-specific treatment protocols exist, but standard approaches for stimulant use disorders — cognitive behavioral therapy, contingency management, and peer support — are applicable. Medical supervision during withdrawal is advisable given the documented neurochemical disruption.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency
The following signs indicate an immediate medical emergency: chest pain or irregular heartbeat; seizures; loss of consciousness or inability to respond; body temperature hot enough to feel through clothing; severe confusion, aggression, or agitation that cannot be de-escalated; muscle rigidity. Excited delirium — extreme agitation, overheating, and incoherence — is the characteristic life-threatening emergency with ephylone.
Immediate steps
- Call emergency services immediately if any of the above signs are present.
- Move the person to a cool, quiet area.
- Remove excess clothing and apply cool (not ice-cold) water to the neck, armpits, and groin to reduce body temperature.
- Place an unconscious person in the recovery position (on their side, airway clear).
- Do not restrain a severely agitated person unless there is immediate danger of self-harm — restraint can worsen overheating and cardiovascular stress.
- Stay with the person until help arrives.
What to tell the dispatcher
State the substance name (ephylone, N-ethylpentylone, or "a synthetic cathinone"), the approximate amount and time taken, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
Ephylone is controlled in multiple jurisdictions; the WHO Expert Committee on Drug Dependence recommended Schedule II under the 1971 Convention in 2018, and several individual nations have adopted stricter controls.[11]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Temporary placement August 31, 2018, citing 151 deaths since 2015;[5] permanent Schedule I effective June 14, 2021.[4] |
| United Kingdom | Controlled under Psychoactive Substances Act 2016 | Blanket ban on non-exempted psychoactive substances; not individually scheduled under the Misuse of Drugs Act 1971. |
| Netherlands | Opium List II | Added July 1, 2025.citation needed |
| Taiwan | Controlled drug | Controlled since December 2017.[2] |
| Australia | Likely Schedule 9 (Prohibited Substance) | Covered under broad cathinone provisions of the Poisons Standard; specific scheduling date not confirmed.citation needed |
| Canada | Not specifically confirmed as of 2024 | Health Canada 2024 NPS report did not specifically list ephylone; may be captured under analog provisions.citation needed |
| International (WHO/UN) | Schedule II (1971 Convention on Psychotropic Substances) | Recommended by ECDD 41st meeting, 2018.[11] |
Legal status changes frequently and varies by jurisdiction. This information is not legal advice — verify current regulations locally before taking any action.
references
- [1]
- [2]
- [3]
- [4]
- [5]
- [6] ^abcdefEspinosa-Velasco M, Reguilón MD, Bellot M, Nadal-Gratacós N, Berzosa X, Puigseslloses P, Gómez-Canela C, Rodríguez-Arias M, Pubill D, Camarasa J, Escubedo E, López-Arnau R (2022) Behavioural and neurochemical effects after repeated administration of N-ethylpentylone (ephylone) in mice. — Journal of Neurochemistry doi:10.1111/jnc.15542